You are here

Generic Version of Marinol Launched

CORONA, Calif., June 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths. Dronabinol is the generic version of Solvay Pharmaceuticals' MARINOL(R) (dronabinol) CIII Capsules, indicated to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol is also indicated to treat anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). For the 12-months ending December 2007, Solvay reported MARINOL(R) sales of 105 million.

About Dronabinol
Dronabinol should not be used by any patient who has a history of hypersensitivity to any cannabinoid or to sesame oil. Patients should not drive, operate machinery, or engage in hazardous activity until they establish that they can tolerate dronabinol and perform such tasks safely. Dronabinol should be used with caution in patients with a history of seizure disorder; patients with cardiac disorders; patients with a history of substance abuse (including alcohol abuse or dependence); patients with mania, depression, or schizophrenia (along with careful psychiatric monitoring); patients taking sedatives, hypnotics, or other psychoactive drugs; and in elderly patients, pregnant patients, nursing mothers, or pediatric patients. The most common side effects probably related to dronabinol are dizziness, feelings of exaggerated happiness, paranoid reaction, drowsiness, thinking abnormal, abdominal pain, nausea and vomiting.

For full prescribing information please visit https://www.allergan.com/NEWS/News/Watson-Pharmaceuticals-Inc-Is-Now-Actavis-Inc.

Source: Watson Pharmaceuticals

Recent Headlines

Breast Cancer, Gastrointestinal Tumors Most Common Types
Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens